Navigation Links
NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
Date:2/27/2008

er studies and there was a trend in favor of treatment. We will continue to evaluate whether the cumulative clinical data from our clinical studies may be able to support evidence of efficacy in HIV-DSP."

The study, a multi-center, double-blind, controlled Phase 3 clinical trial in a total of 494 patients, was similar in design to the Company's previous successfully completed phase 3 study in HIV-DSP. Study C119 contained two treatment arms (30-minute and 60-minute arms) for both NGX-4010 and a control patch containing a low concentration of the same active ingredient as NGX- 4010. When looking at the individual treatment arms, the 30-minute group treated with NGX-4010 achieved a 26.1% reduction in pain from baseline compared to 19.1% for the control group (p=0.1) and the 60-minute group treated with NGX-4010 achieved a 32.8% reduction in pain from baseline compared to 30.1% for the control group (p=0.5). Secondary endpoints also did not achieve statistical significance.

Anthony DiTonno, Chief Executive Officer, commented, "We remain focused on our overall goal of achieving commercial launch of NGX-4010 in 2009. We are on track to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) later this year in postherpetic neuralgia (PHN), and are continuing with the Marketing Authorization Application (MAA) under the centralized procedure in the Europe Union where our application for approval was accepted by the European Medicines Agency (EMEA) in September of last year. We expect to consult with both regulatory agencies in the coming weeks to discuss how the results of this most recently completed trial, when taken in the context of the entire clinical development record of NGX-4010, which has been studied in over 1,600 patients, may support gaining an approval broader than the potential PHN indication. "

NGX-4010 is a dermal patch containing capsaicin, a selective TRPV1 agonist, designed to manage peripheral neuropathic p
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
4. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
5. Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
6. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
7. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
8. amfAR Announces Funding for HIV Services and Research Aimed at Men Who Have Sex With Men in Developing Countries
9. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
10. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
11. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)...  BioPharmX Corporation (NYSE MKT: BPMX) today announced the ... 3,636,364 shares of its common stock at a price ... granted the underwriters a 30-day option to purchase up ... public offering price. In addition, Korea Investment ... agreed to purchase 1,081,081 shares of common stock from ...
(Date:7/1/2015)... SAN FRANCISCO , July 1, 2015 ... health market) is expected to reach USD 49,119.2 million ... View Research, Inc. Monitoring services is expected to remain ... revenue of USD 1,227.5 million in 2012, and an ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ...
(Date:7/1/2015)... , July 1, 2015 ... its Executive Board. Mr. Gert Weber has ... Invest AG as Chief Executive Officer (CEO) ... July 1 st , 2015. Mr. Weber brings more ... technological industries and has filled various executive management positions, ...
Breaking Medicine Technology:BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 2BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 2mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 5Haselmeier Group Announces the Extension and Reorganization of its Executive Board 2
... 2011 /PRNewswire/ -- PRA, a leading Clinical ... Romania to further strengthen our coverage of the Balkan ... projects in the neighboring Republic of Moldova. ... in Romania, the PRA staff has steadily increased and ...
... Aug. 22, 2011 Reportlinker.com announces ... is available in its catalogue: ... Assessments of Leading Suppliers ... This report provides diagnostic imaging industry ...
Cached Medicine Technology:PRA Opens Office in Romania 2Global MRI Market: Strategic Assessments of Leading Suppliers 2Global MRI Market: Strategic Assessments of Leading Suppliers 3Global MRI Market: Strategic Assessments of Leading Suppliers 4Global MRI Market: Strategic Assessments of Leading Suppliers 5
(Date:7/1/2015)... ... ... Did you know that infertility in men is more common than couples ... Center of Texas (AFCT) would like to talk about some natural ways to increase ... be a “woman’s issue,” male fertility factors can play a role in about 40% ...
(Date:7/1/2015)... ... , ... Lisa Keys, the widow of U.S. Army Master Sergeant Bradley Keys, ... memory of her late husband and all of America’s fallen military and first responders. ... died during a Special Forces training exercise in December of 2012. The ‘Legacy 5K’ ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Convoy of ... community celebration in the Twin Cities on Saturday, August 1, at Spring Lake Park ... community will provide more than $1 million worth of goods and services including free ...
(Date:7/1/2015)... ... ... Trevor L. Williams, DMD holds a Bachelor of Science degree in Biomedical ... degree in Microbiology. He graduated from the University of Florida College of Dentistry in ... Association and the Academy of General Dentistry. Dr. Williams was born in Tampa and ...
(Date:7/1/2015)... ... 01, 2015 , ... Scoliosis is a disorder in which the normally straight vertical line of ... to 3 percent of the population, or an estimated 6 to 9 million people. While ... the ages of 10 and 15. Most types of scoliosis are more common in girls ...
Breaking Medicine News(10 mins):Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 2Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 4Health News:Wife of Fallen Special Forces Soldier to Host Nationwide ‘Virtual 5K’ for Charity 2Health News:Wife of Fallen Special Forces Soldier to Host Nationwide ‘Virtual 5K’ for Charity 3Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:Trevor L. Williams, D.M.D. Joins Enlow & Vance Dental Partners in Tampa, Florida 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 3Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 4
... SEPTEMBER 23, 2009 Late-breaking data from SPIRIT IV, ... the U.S., shows that an everolimus-eluting stent demonstrated enhanced ... native coronary artery lesions when compared to a paclitaxel-eluting ... achieved with drug-eluting stents without sacrificing safety. ...
... , ... innovative CHO cell culture supplement from InVitria designed to deliver superior growth, maximum antibody productivity ... in Jackson Hole, WY this week. , ... Fort Collins, CO (PRWEB) September 23, 2009 -- A new powerful and robust ...
... ... ... United Nations Foundation and the Kingdom of Saudi Arabia announced today that the ... to be eliminated from the world. The vast majority of the world is now ...
... , , LIVINGSTON, ... to combine ultrasonic visualization beneath the skin surface with non-invasive delivery ... of the skin. Reflections, Center for Skin and Body, in Livingston ... new technology. , , "We are very excited ...
... , STAMFORD, Conn., Sept. 23 ... across the United States at the 2009 Clinton Global Initiative ... by President & CEO Curt Welling, is a two-year commitment ... to health care organizations serving the uninsured and underinsured throughout ...
... New Rochelle, NY, September 23, 2009The commercial failure of ... product to come to market, led other companies such ... delivery in development intended to compete for a share ... for efforts to deliver insulin via the lungs? The ...
Cached Medicine News:Health News:SPIRIT IV trial shows everolimus stent sets new standard for event-free survival 2Health News:InVitria Presents Zap-CHO Performance Results at PEACe Conference 2Health News:InVitria Presents Zap-CHO Performance Results at PEACe Conference 3Health News:The Kingdom of Saudi Arabia Commits $30 Million to Polio Eradication Efforts 2Health News:The Kingdom of Saudi Arabia Commits $30 Million to Polio Eradication Efforts 3Health News:New Procedure Raises Brows Without Surgery Or Injectibles 2Health News:AmeriCares Expands Medical Assistance Across the United States 2Health News:AmeriCares Expands Medical Assistance Across the United States 3Health News:Is inhaled insulin delivery still a possibility? Why has it been a commercial failure? 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: